Latest news with #DavidsonCompany
Globe and Mail
10 hours ago
- Business
- Globe and Mail
First Nordic Announces Annual General Meeting Voting Results
TORONTO , /CNW/ - First Nordic Metals Corp. (" First Nordic" or the " Company") (TSXV: FNM) (FNSE: FNMC SDB) (OTCQB: FNMCF) (FRA: HEG0) is pleased to announce the results of the Company's Annual General and Special Meeting of Shareholders (the "Meeting") held on June 25, 2025 . A total of 49,884,492 common shares were represented in person or by proxy at the Meeting, representing approximately 18% of the votes attached to all outstanding common shares of the Company as at the record date. All the matters submitted to the shareholders, as set out in the Notice of Meeting dated May 22, 2025 , were voted in favor. The number of directors elected at the Meeting was seven (7) and the directors will hold office until the next annual meeting of shareholders or until their successors are elected or appointed: Director Votes For % Votes For Votes Withheld % Votes Withheld Taj Singh 42,922,105 90.23 % 4,646,469 9.77 % Adam Cegielski 46,183,058 97.09 % 1,385,516 2.91 % Toby Pierce 43,186,025 90.79 % 4,382,549 9.21 % Brendan Cahill 46,149,050 97.02 % 1,419,524 2.98 % Henrik Lundin 47,562,670 99.99 % 5,904 0.01 % Marc Legault 47,561,425 99.98 % 7,149 0.02 % Jeffrey Couch 46,180,025 97.08 % 1,388,549 2.92 % At the Meeting the shareholders also approved the reappointment of Davidson & Company LLP, Chartered Professional Accountants, and the directors were authorized to fix the remuneration to be paid to the auditors. Further details regarding the resolutions and voting results are available in the Report of Voting Results, which has been filed under the Company's profile on the Nasdaq First North website. ABOUT FIRST NORDIC METALS First Nordic Metals Corp. is a Canadian-based gold exploration company, consolidating assets in Sweden and Finland , with a vision to create Europe's next gold camp. The Company's flagship asset is the Barsele gold project in northern Sweden , a joint venture project with senior gold producer Agnico Eagle Mines Limited. Immediately surrounding the Barsele project, FNM is 100%-owner of a district-scale license position comprised of two additional projects (Paubäcken, Storjuktan), which combined with Barsele, total approximately 100,000 hectares on the Gold Line greenstone belt. Additionally, in northern Finland , FNM is the 100%-owner of a district-scale position covering the entire underexplored Oijärvi greenstone belt, including the Kylmäkangas deposit, the largest known gold occurrence on this belt. ON BEHALF OF THE BOARD OF DIRECTORS Taj Singh , CPA CEO & Director For further information contact: Marie Macdonald Investor Relations 604-687-8566 info@ Follow First Nordic Metals: Twitter: @fnmetals Youtube: @firstnordicmetalscorp LinkedIn: @firstnordicmetals Facebook: @FirstNordicMetals Instagram: @firstnordicmetals Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward-Looking Statements This news release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates and includes, statements with respect to (i) the NBU Acquisition, (ii) issuance of Shares thereunder, and (iii) receipt of TSXV approval of the NBU Acquisition. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this news release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that they will materialize or that the assumptions on which it is based are correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this news release are free from errors and readers of this news release should not place undue reliance on the forward-looking statements in this news release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of the date of this news release and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this news release, unless it is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
Yahoo
15 hours ago
- Business
- Yahoo
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announce the results of voting at its 2025 annual general meeting of shareholders held on June 25, 2025, in Vancouver, British Columbia (the 'Meeting'). All five members of the Company's board of directors named as nominees in its management information circular dated May 26, 2025 (the 'Circular') were elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia, Yevgeniy Meshcherekov and Dr. David Kideckel. In addition, at the Meeting, the shareholders of the Company: (i) approved the re-appointment of Davidson & Company LLP as the Company's auditor until the next annual general meeting of shareholders; (ii) approved the setting of the number of directors at five; and (iii) re-approved the Company's existing omnibus equity incentive plan as set out in the Circular. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, they can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Notice Regarding Forward-Looking Statements This press release may contain 'forward-looking statements' regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: the Company's objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company's DDR platform. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'is expected', 'expects', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at For Further Information Contact: Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ('Cronos' or the 'Company') today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the 'Meeting'), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the election of directors are as follows: Name of Director Number of Shares Voted For Percentage of Shares Voted For Number of Shares Withheld from Voting Percentage of Shares Withheld from Voting Michael Gorenstein 206,219,875 92.38% 17,012,443 7.62% Jason Adler 215,665,946 96.61% 7,566,372 3.39% Murray Garnick 215,548,312 96.56% 7,684,006 3.44% Kamran Khan 216,349,694 96.92% 6,882,624 3.08% Dominik Meier 216,404,347 96.94% 6,827,971 3.06% Elizabeth Seegar 211,177,232 94.60% 12,055,086 5.40% James Rudyk 215,956,203 96.74% 7,276,115 3.26% Shareholders also approved an advisory (non-binding) resolution on the compensation of the Company's named executive officers, with 94.13% of votes cast in favor of such resolution, and approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2025 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at and the Company's Form 8-K filed on EDGAR at About Cronos Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: For further information, please contact:Harrison AaronInvestor RelationsTel: (416)
Yahoo
7 days ago
- Business
- Yahoo
Entrée Resources Announces 2025 AGM Results
VANCOUVER, British Columbia, June 19, 2025 (GLOBE NEWSWIRE) -- Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the 'Company' or 'Entrée') is pleased to announce the results of voting at its annual general meeting of shareholders which was held today (the 'Meeting'). All matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Information Circular, both dated May 13, 2025, were approved by the requisite majority of votes cast at the Meeting. NUMBER OF DIRECTORSShareholders approved setting the number of directors at six. ELECTION OF DIRECTORSThe details of the voting results for the election of directors are set out below: Votes For Withheld Votes Director # % # % Teresa Conway 107,785,288 96.79 3,573,883 3.21 Alan Edwards 107,700,649 96.71 3,658,522 3.29 Allan Moss 107,790,362 96.80 3,568,809 3.20 Michael Price 107,700,662 96.71 3,658,509 3.29 Paula Rogers 107,791,588 96.80 3,567,583 3.20 Stephen Scott 107,792,822 96.80 3,566,349 3.20 APPOINTMENT OF AUDITORSDavidson & Company LLP, Chartered Professional Accountants was re-appointed auditors of the Company for the ensuing year at the remuneration to be fixed by the directors. Detailed voting results for the Meeting are available on SEDAR+ at and OTC Markets at ABOUT ENTRÉE RESOURCES LTD. Entrée Resources Ltd. is a well-funded Canadian mining company with a unique carried joint venture interest on a significant portion of one of the world's largest copper-gold projects – the Oyu Tolgoi project in Mongolia. Entrée has a 20% or 30% carried participating interest in the Entrée/Oyu Tolgoi joint venture, depending on the depth of mineralization. Horizon Copper Corp. and Rio Tinto are major shareholders of Entrée, beneficially holding approximately 24% and 16% of the shares of the Company, respectively. More information about Entrée can be found at FURTHER INFORMATION David JanInvestor Relations Entrée Resources Ltd. Tel: 604-687-4777 | Toll Free: 1-866-368-7330 E-mail: djan@
